H
HistoWiz
Provides automated histopathology for biomedical researchers
About HistoWiz
HistoWiz, Inc. provides automated histopathology services for researchers in the academic, biotechnology, and pharmaceutical sectors. The company was founded in 2012 by Ke Cheng, PhD, who now serves as a board member. The idea for the company stemmed from Dr. Cheng's own frustrations with the slow and inefficient workflow of traditional histopathology while working as a cancer researcher at Harvard and the Swiss Institute of Experimental Cancer Research. HistoWiz began operations in Brooklyn, NY, in January 2013. The company's business model centers on streamlining the histopathology process. Clients mail formalin-fixed tissue specimens to HistoWiz's labs. The company then handles tissue processing, embedding, sectioning, and staining, utilizing automation to ensure rapid turnaround times, often as fast as 48 hours. The results are digitized as high-resolution, whole-slide images and uploaded to a proprietary, cloud-based platform called PathologyMap™. This platform allows clients to instantly view, manage, analyze, and share their results from any computer or mobile device without needing to download large files. Revenue is generated through its service offerings, which can be paid for via credit card or purchase orders. HistoWiz offers a comprehensive suite of services, including precision histology (H&E and special stains), immunostaining (IHC, ISH, and multiplex IF), and slide archiving with bulk whole-slide imaging.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- New York City, United States
- Employees
- 49
- Open positions
- 11
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, YC W16, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2021 | $32M | $128M | Vivo Capital · venBio Partners · Jon Oringer | — |
| SEED✓Equity / VC | Feb 2018 | $2.8M | $11M | Undisclosed | — |
Growth signals
Latest recorded traffic for HistoWiz is 7.4K monthly website visits, down 38.3% over the last three months. HistoWiz's team declined 12.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
ZhenFund
Y Combinator
Techammer
Series A3 investors entered at this stage
Vivo Capital
venBio Partners
Jon Oringer
Other known investors3 additional known investors
Asahi Kasei Ventures
Downstate Biotechnology Incubator
MicroVentures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HistoWiz on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HistoWiz’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.